Partner Content Partner Content Why Does Quant-Led KOL Identification Fail In Growth Markets... When it comes to KOL identification mapping, there is no shortage of quant data around KOL and HCP activity out there.
Partner Content Partner Content Pathway To Effective Stakeholder Mapping Before developing any stakeholder engagement plan, it is crucial to have a clear understanding of all the relevant individuals and groups your product or device could directly impact or interest in
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
